SAN MATEO, Calif.--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that results from clinical and preclinical studies demonstrating the ability of tranilast to reduce serum uric acid levels and monosodium urate crystal-induced inflammation – two important risk factors for gout – were presented at The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology in Rome, Italy, June 16-19, 2010.
